Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Panbela Therapeutics Inc. (PBLA : OTC)
 
 • Company Description   
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics Inc., formerly known as Sun BioPharma Inc., is based in MINNEAPOLIS.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.27 Daily Weekly Monthly
20 Day Moving Average: 15,567 shares
Shares Outstanding: 4.85 (millions)
Market Capitalization: $1.31 (millions)
Beta: 1.34
52 Week High: $0.47
52 Week Low: $0.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.33% 2.35%
12 Week -3.39% -18.74%
Year To Date -28.82% -33.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
712 VISTA BLVD SUITE 305
-
WACONIA,MN 55387
USA
ph: 952-479-1196
fax: -
ir@panbela.com http://www.panbela.com
 
 • General Corporate Information   
Officers
Jennifer K. Simpson - Chief Executive Officer and President
Michael T. Cullen - Chairman
Susan Horvath - Chief Financial Officer; Treasurer and Secretary
Daniel J. Donovan - Director
Jeffrey E. Jacob - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 69833W404
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/24
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 4.85
Most Recent Split Date: 1.00 (0.05:1)
Beta: 1.34
Market Capitalization: $1.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 97.25%
vs. Previous Quarter: -0.68%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©